Dengue test solutions for every disease stage

Dengue is one of the most rapidly spreading infectious diseases worldwide. Between 2000 and 2019, the number of cases increased tenfold. Half of all people now live in areas where dengue is endemic1.

One of the reasons for this is global warming, which greatly favours the spread of the tiger mosquitoes (Aedes aegypti and Aedes albopictus) that act as vectors for dengue. In many endemic areas, the rising temperatures and heavier rainfall associated with climate change contribute to an increase in the number of mosquitoes2.

1 WHO: Dengue and severe dengue; Dengue - Global situation as of 21 December 2023
2 WHO: Dengue - Global situation as of 30 May 2024

Infection diagnostics with EUROIMMUN

Specifically for dengue virus infections, we offer you diagnostic solutions for all stages of the disease - from the onset of the first symptoms to the end of the disease.

You're invited to the Today's Clinical Lab Infectious Disease & Antimicrobial Resistance Digital Forum event!

Register for free and view the on-demand presentation of the EUROIMMUN session "Dengue Infection: Effective Strategies for Accurate Detection During Global Surge" from July 9, 2024.

Learn more: Today's Clinical Lab Digital Forum

With over 35 years of experience in the field of laboratory diagnostics, we develop and distribute complete diagnostic solutions that are tailored to your needs. We have one of the broadest portfolios of serological tests for the diagnostics of emerging diseases, which are becoming increasingly relevant.
Emerging diseases

Reliable diagnostics of dengue virus infections in all disease stages

Adapted from Ohst C et al.,
Reliable serological testing for the diagnosis of emerging infectious diseases. Adv Exp Med Biol 1062:19-43 (2018).

Antigen detection

  • Dengue Virus NS1 Antigen ELISA (types 1-4)

Detection of the viral protein NS1:
Early marker for acute infections – positive laboratory results already at the first symptoms!


Antibody detection

  • Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG)
  • Anti-Dengue Virus Type 1-4 ELISA (IgG, IgM)
  • Anti-Dengue Virus IIFT (IgG, IgM)
  • Flavivirus/Arbovirus IIFT Mosaics (IgG, IgM)

Identification of acute and past infections
Screening and investigation of cross reactions

Importance of antibody testing in the context of dengue vaccination

Our products make a valuable contribution not only to diagnostics, but also to screening prior to vaccination with the first dengue vaccine, which was launched on the market in 2015*.

This is because the CYD-TDV vaccine (Dengvaxia) is only administered to people who live in endemic areas and have been proven to have been infected with the dengue virus. The CDC (Centers for Disease Control and Prevention) therefore recommends double testing with two specific test systems for the detection of IgG antibodies against dengue. One of the two test systems of this two-step algorithm is the EUROIMMUN Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG)3.
3 CDC: Laboratory Testing Requirements for Vaccination with Dengvaxia Dengue Vaccine

Product details

Qdenga, another vaccine against dengue, has been available since 2022*. Further vaccines are currently in development.

* Approval date varies depending on the country


The importance of reliable testing - a patient story from Puerto Rico

Watch this video – See how challenging a dengue infection can be for
patients and their relatives (English subtitles).


More information


If you have any questions, please do not hesitate to contact us:

Product Management Infection Diagnostics


Or get in touch with your local contact person

Find your local distributor

Editorial: Innovations for infectious disease diagnostics

EUROIMMUN offers an extensive range of test systems for infection diagnostics, including serological
assays for antibody determination and PCR-based tests for direct pathogen detection. For the growing
field of emerging diseases, EUROIMMUN boasts one of the largest portfolios of antibody tests
worldwide to support diagnosis and surveillance of upsurging viral and parasitic infections.
Read more

Featured in PPC, April 2024

Back to top
Contact person on site
Please click on a country or enter yours
North America
South & Central America
Middle East & Africa